[1] Daemen M J, Lombardi DM, Bosman FT, et al. Angiotensin Ⅱ induces smooth muscle cell proliferation in the normal and injured rat arterial wall [J]. Circ Res, 1991, 68(2): 450-6. [2] Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin Ⅱ receptor gene expression by low-density lipoprotein in vascular smooth muscle cells [J]. Circulation, 1997,95(2): 473-8. [3] Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril: The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group [J]. J Am Coll Cardiol,1995, 25(2): 362-9. [4] Ribichini F, Wijns W, Ferrero V, et al. Effect of angiotensinconverting enzyme inhibition on restenosis after coronary stenting [J]. Am J Cardiol, 2003, 91(2): 154-8. [5] Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn[J]. J Am Coll Cardiol, 2004, 44(7): 1373-85. [6] Dundar Y, Hill RA, Bakhai A, et al. Angioplasty and stents in coronary artery disease: a systematic review andmeta-analysis [J]. Scand Cardiovasc J, 2004, 38(4): 200-10. [7] Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation,signalling and function[J]. Blood Press, 2003, 12(2): 70-88. [8] Ohishi M, Ueda M, Rakugi H, et al. Upregulation of angiotensinconverting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans [J].Circulation, 1997, 96(10): 328-37. [9] Andres V, Castro C. Antiproliferative strategies for the treatment of vascular proliferative disease [J]. Curr Vasc Pharmacol, 2003, 1:85-98. |